Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ASH 2015

5 - 7 Dec 2015
TBC, Orlando, United States of America
ASH 2015: Latest in CLL
Prof John Gribben, Prof Stephan Stilgenbauer, Dr Alessandra Tedeschi, Dr Patrick...
ASH 2015: Latest in CLL ( Prof John Gribben, Prof Stephan Stilgenbauer, Dr Alessandra Tedeschi, Dr Patrick Thornton )
7 Dec 2015
Long-term outcomes after blinatumomab treatment for ALL
Dr Nicola Gökbuget - University of Frankfurt, Frankfurt, Germany
Long-term outcomes after blinatumomab treatment for ALL ( Dr Nicola Gökbuget - University of Frankfurt, Frankfurt, Germany )
7 Dec 2015
ASH 2015: Highlights
ecancertv
ASH 2015: Highlights ( ecancertv )
7 Dec 2015
How is cancer-related venous thromboembolism treated in real world practice?
Prof Alok Khorana - Cleveland Clinic, Cleveland, USA
How is cancer-related venous thromboembolism treated in real world practice? ( Prof Alok Khorana - Cleveland Clinic, Cleveland, USA )
7 Dec 2015
Dalteparin thromboprophylaxis for cancer patients at high risk of venous thrombo...
Prof Alok Khorana - Cleveland Clinic, Cleveland, USA
Dalteparin thromboprophylaxis for cancer patients at high risk of venous thromboembolism ( Prof Alok Khorana - Cleveland Clinic, Cleveland, USA )
7 Dec 2015
Response to rituximab induction is a predictive biomarker in post-transplant lym...
Prof Corrado Tarella - Istituto Europeo di Oncologia, Milano, Italy
Response to rituximab induction is a predictive biomarker in post-transplant lymphoproliferative disorder ( Prof Corrado Tarella - Istituto Europeo di Oncologia, Milano, Italy )
7 Dec 2015
“Low but real” risk of myelodysplastic syndromes caused by thyroid cancer treatm...
Dr Sudipto Mukherjee - Cleveland Clinic, Cleveland, USA
“Low but real” risk of myelodysplastic syndromes caused by thyroid cancer treatment ( Dr Sudipto Mukherjee - Cleveland Clinic, Cleveland, USA )
7 Dec 2015
High dose chemotherapy plus transplant remains standard care for young newly dia...
Dr Francesca Gay - University of Torino, Torino, Italy
High dose chemotherapy plus transplant remains standard care for young newly diagnosed multiple myeloma patients ( Dr Francesca Gay - University of Torino, Torino, Italy )
7 Dec 2015
ENDEAVOR: carfilzomib new standard in multiple myeloma?
Dr Keith Stewart - Mayo Clinic, Rochester, USA
ENDEAVOR: carfilzomib new standard in multiple myeloma? ( Dr Keith Stewart - Mayo Clinic, Rochester, USA )
7 Dec 2015
How can functional drug screening guide personalised cancer therapy?
Prof Jeff Tyner - Oregon Health & Science University, Portland, USA
How can functional drug screening guide personalised cancer therapy? ( Prof Jeff Tyner - Oregon Health & Science University, Portland, USA )
7 Dec 2015
How do genes influence the development of chronic idiopathic thrombocytopenic pu...
Prof Jenny Despotovic - Texas Children's Cancer Center, Houston, USA
How do genes influence the development of chronic idiopathic thrombocytopenic purpura? ( Prof Jenny Despotovic - Texas Children's Cancer Center, Houston, USA )
7 Dec 2015
Combining treatment options for higher risk myelodysplastic syndromes and chroni...
Dr Mikkael Sekeres - Cleveland Clinic Foundation, Cleveland, USA
Combining treatment options for higher risk myelodysplastic syndromes and chronic myelomonocytic leukaemia ( Dr Mikkael Sekeres - Cleveland Clinic Foundation, Cleveland, USA )
7 Dec 2015
ASH 2015: Highlights in mantle cell lymphoma
Prof Simon Rule and Prof Steven Le Gouill
ASH 2015: Highlights in mantle cell lymphoma ( Prof Simon Rule and Prof Steven Le Gouill )
7 Dec 2015
Incidence of and predictors for early death in paediatric patients with acute pr...
Dr Oussama Abla - The Hospital for Sick Children, Toronto, Canada
Incidence of and predictors for early death in paediatric patients with acute promyelocytic leukaemia ( Dr Oussama Abla - The Hospital for Sick Children, Toronto, Canada )
6 Dec 2015
Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leu...
Prof Giovanni Martinelli - University of Bologna, Bologna, Italy
Blinatumomab has promising effect on hard-to-treat, rare acute lymphoblastic leukaemia subtype ( Prof Giovanni Martinelli - University of Bologna, Bologna, Italy )
6 Dec 2015
Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia
Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France
Rituximab plus chemotherapy improves outcomes in acute lymphoblastic leukaemia ( Dr Sébastien Maury - Hôpital Henri Mondor, Créteil, France )
6 Dec 2015
First all-oral treatment for relapsed and treatment-resistant multiple myeloma
Prof Philippe Moreau - University of Nantes, Nantes, France
First all-oral treatment for relapsed and treatment-resistant multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
6 Dec 2015
Experimental oral therapy for high-risk CLL shows promise
Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany
Experimental oral therapy for high-risk CLL shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )
6 Dec 2015
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, ...
Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )
6 Dec 2015
Idelalisib combination therapy in relapsed or treatment-resistant CLL better tha...
Dr Andrew Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA
Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen ( Dr Andrew Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
ASH 2015: Novel combination approaches for multiple myeloma
Prof Marivi Mateos, Prof Sagar Lonial, Dr Torben Plesner, Prof Meletios Dimopoul...
ASH 2015: Novel combination approaches for multiple myeloma ( Prof Marivi Mateos, Prof Sagar Lonial, Dr Torben Plesner, Prof Meletios Dimopoulos )
6 Dec 2015
ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia
Prof John Gribben and Prof Stilgenbauer
ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia ( Prof John Gribben and Prof Stilgenbauer )
6 Dec 2015
ASH 2015: New targeted therapies for haematological malignancies
Dr Robert Hromas - University of Florida, Gainesville, USA
ASH 2015: New targeted therapies for haematological malignancies ( Dr Robert Hromas - University of Florida, Gainesville, USA )
6 Dec 2015
Using epigenetics to manipulate cancer cells
Dr Stephen Nimer - Sylvester Comprehensive Cancer, Miami, USA
Using epigenetics to manipulate cancer cells ( Dr Stephen Nimer - Sylvester Comprehensive Cancer, Miami, USA )
6 Dec 2015
Overcoming the barriers of the P53 dysfunction to cure blood cancers
Dr Guillermina Lozano - MD Anderson Cancer Center, Houston, USA
Overcoming the barriers of the P53 dysfunction to cure blood cancers ( Dr Guillermina Lozano - MD Anderson Cancer Center, Houston, USA )
6 Dec 2015
Exciting new immunosuppressive therapy treatment for aplastic anaemia
Dr Danielle Townsley - George Washington University School of Medicine, Washingt...
Exciting new immunosuppressive therapy treatment for aplastic anaemia ( Dr Danielle Townsley - George Washington University School of Medicine, Washington, USA )
6 Dec 2015
Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia show...
Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany
Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )
6 Dec 2015
Combination therapy with idelalisib better prevents disease progression in relap...
Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA
Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen ( Dr Andrew D. Zelenetz - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
Study underscores promise of targeted therapies as first-line approach for patie...
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, ...
Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )
6 Dec 2015
First targeted therapy for multiple myeloma effective against hard-to-treat dise...
Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle, Denma...
First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle, Denmark )
6 Dec 2015
First targeted therapy for genetically defined subset of patients with acute mye...
Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA
First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia  significantly improves survival ( Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA )
6 Dec 2015
Exciting evidence for first all-oral treatment for relapsed and treatment-resist...
Prof Philippe Moreau - University of Nantes, Nantes, France
Exciting evidence for first all-oral treatment for relapsed and treatment-resistant multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
6 Dec 2015
Study finds new use for rituximab in acute lymphoblastic leukaemia
Prof Sébastien Maury - Hôpital Henri Mondor, Créteil, France
Study finds new use for rituximab in acute lymphoblastic leukaemia ( Prof Sébastien Maury - Hôpital Henri Mondor, Créteil, France )
6 Dec 2015
First targeted therapy for multiple myeloma effective against hard-to-treat dise...
Dr Torben Plesner - Vejle Hospital, Vejle, Denmark
First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, Vejle, Denmark )
6 Dec 2015
First targeted therapy for genetically defined subset with acute myeloid leukaem...
Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA
First targeted therapy for genetically defined subset with acute myeloid leukaemia significantly improves survival ( Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA )
6 Dec 2015
Variants for increased risk of osteonecrosis in paediatric acute lymphocytic leu...
Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA
Variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified ( Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA )
6 Dec 2015
Immunotherapy makes patients’ tumours "melt away"
Dr Joshua Brody - Mount Sinai Medical Center, New York, USA
Immunotherapy makes patients’ tumours "melt away" ( Dr Joshua Brody - Mount Sinai Medical Center, New York, USA )
6 Dec 2015
Quality assessment looking at rivaroxaban for cancer-related thrombosis
Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA
Quality assessment looking at rivaroxaban for cancer-related thrombosis ( Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
Guidance for anticoagulation management in the setting of thrombocytopenia in ca...
Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA
Guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients ( Dr Gerald Soff - Memorial Sloan Kettering Cancer Center, New York, USA )
6 Dec 2015
Genetic variant that signifies higher risk for avascular necrosis in children wi...
Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA
Genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA )
6 Dec 2015
Tosedostat for elderly acute myeloid leukaemia
Dr Giuseppe Visani - Ospedale S. Salvatore, Pesaro, Italy
Tosedostat for elderly acute myeloid leukaemia ( Dr Giuseppe Visani - Ospedale S. Salvatore, Pesaro, Italy )
5 Dec 2015
ASH 2015: Monoclonal antibodies for multiple myeloma
Dr Saad Usmani and Prof Thierry Facon
ASH 2015: Monoclonal antibodies for multiple myeloma ( Dr Saad Usmani and Prof Thierry Facon )
5 Dec 2015
Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
5 Dec 2015
Daratumumab for multiple myeloma
Prof Sagar Lonial - Emory University School of Medicine, Atlanta, USA
Daratumumab for multiple myeloma ( Prof Sagar Lonial - Emory University School of Medicine, Atlanta, USA )
5 Dec 2015
Children most at risk of over-reporting adherence to at-home chemotherapy regime...
Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA
Children most at risk of over-reporting adherence to at-home chemotherapy regimen ( Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA )
5 Dec 2015
Cancer-associated thrombosis: Switching patients to warfarin after 6-month compl...
Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada
Cancer-associated thrombosis: Switching patients to warfarin after 6-month completion of anticoagulant treatment ( Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada )
5 Dec 2015
Study suggests warfarin is acceptable for long-term treatment of cancer-associat...
Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada
Study suggests warfarin is acceptable for long-term treatment of cancer-associated thrombosis ( Dr Chatree Chai-Adisaksopha - McMaster University, Hamilton, Canada )
5 Dec 2015
Researchers identify children most at risk of over-reporting adherence to at-hom...
Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA
Researchers identify children most at risk of over-reporting adherence to at-home chemotherapy regimen ( Dr Wendy Landier - University of Alabama at Birmingham, Birmingham, USA )
5 Dec 2015
Research provides guidance for anticoagulation management in the setting of thro...
Dr Gerald A. Soff - Memorial Sloan Kettering Cancer Center, New York, USA
Research provides guidance for anticoagulation management in the setting of thrombocytopenia in cancer patients ( Dr Gerald A. Soff - Memorial Sloan Kettering Cancer Center, New York, USA )
5 Dec 2015
Promising new strategy for treating children with acute lymphocytic leukaemia
Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA
Promising new strategy for treating children with acute lymphocytic leukaemia ( Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA )
5 Dec 2015
Comment: Whole exome sequencing finds genes associated with autoimmune platelet ...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Whole exome sequencing finds genes associated with autoimmune platelet disorder in children ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Comment: Classification system based on cytogenetics and treatment response iden...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Classification system based on cytogenetics and treatment response identifies leukaemia patients with high-risk clinical features ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Comment: Study identifies genetic variant that signifies higher risk for avascul...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Comment: Genetic variants for increased risk of osteonecrosis in paediatric acut...
Dr Wendy Stock - University of Chicago, Chicago, USA
Comment: Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified ( Dr Wendy Stock - University of Chicago, Chicago, USA )
5 Dec 2015
Engineered cells to target multiple myeloma
Dr James Kochenderfer - National Cancer Institute, Bethesda, USA
Engineered cells to target multiple myeloma ( Dr James Kochenderfer - National Cancer Institute, Bethesda, USA )
5 Dec 2015
Whole exome sequencing finds genes associated with autoimmune platelet disorder ...
Dr Jenny M. Despotovic - Texas Children’s Cancer and Hematology Centers, Houston...
Whole exome sequencing finds genes associated with autoimmune platelet disorder in children ( Dr Jenny M. Despotovic - Texas Children’s Cancer and Hematology Centers, Houston, USA )
5 Dec 2015
Classification system based on cytogenetics and treatment response identifies le...
Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA
Classification system based on cytogenetics and treatment response identifies leukaemia patients with high risk clinical features with outstanding outcomes ( Dr Elizabeth Raetz - University of Utah, Salt Lake City, USA )
5 Dec 2015
Study identifies genetic variant that signifies higher risk for avascular necros...
Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA
Study identifies genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA )
5 Dec 2015
Genetic variants for increased risk of osteonecrosis in paediatric acute lymphoc...
Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA
Genetic variants for increased risk of osteonecrosis in paediatric acute lymphocytic leukaemia identified ( Dr Seth Karol - St Jude Children's Research Hospital, Tampa, USA )
5 Dec 2015